Investors
2025 Annual Report and Responsible Business Report
Read about our strong performance and pipeline momentum in 2025.
Investors
We announced our full year and fourth quarter 2025 results on Wednesday, 4 February.
Press releases
- GSK’s RSV vaccine, AREXVY, approved in US for expanded age indication in adults aged 18–49 years at increased risk
- GSK’s AREXVY associated with reductions in certain RSV-related risks including heart attack, stroke and severe flare-ups of COPD and asthma, real world study shows
- GSK awards $2M in COiMMUNITY Initiative grants to help close vaccination gaps, commits $3M for 2026

GSK Global links
Visit our Global site for additional features









